Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $40.3352W HIGH $199.20
Volume
50.81 K
Value Traded
1.63 M
Short % Float
16.58%
-0.37%Week
-18.3%1 Month
-9.05%3 Month
-28.43%6 Month
-95.61%5 Year
-96.25%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
130.88 M
EPS (TTM)
-17.87
P/E Ratio
-
Ent. Value
57.03 M
Total Shares
2.87 M
Float Shares
2.51 M
Insiders
12.62%
Institutions
66.93%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
SPRB Catalyst Timeline
Dated clinical, regulatory and corporate events for Spruce Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Spruce Biosciences, Inc.
200Total events
21Upcoming
42Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseCorporate
Cure Sanfilippo Foundation and National MPS Society make $5.5 million strategic investment in Spruce Biosciences
▲Equity OfferingCorporate
Cure Sanfilippo Foundation and National MPS Society make combined $5.5 million strategic investment in Spruce
●Management ChangeCorporate
Jessica Cohen Pfeffer, M.D. appointed Vice President, Clinical Development effective August 3, 2026
●Management ChangeCorporate
Adrian Quartel, M.D., FFPM appointed Chief Medical Officer effective July 27, 2026
◆Oral PresentationPresentation
Spruce Biosciences to present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
◆Management ChangeCorporate
Appointment of Eric Jordan as VP, Marketing and Tina Gullotta as VP, Finance and Corporate Controller
◆Oral PresentationPresentation
Long-term tralesinidase alfa ERT data presented at 18th International MPS Symposium
Sanfilippo Syndrome Type B (MPS IIIB)source ↗
◆Oral Presentationtralesinidase alfaPresentation
Long-term data on tralesinidase alfa (TA-ERT) to be presented at 18th International MPS Symposium
Sanfilippo Syndrome Type B (MPS IIIB)source ↗
▲Debt Royalty FinancingCorporate
Secured up to $50 million growth capital from Avenue Capital Group
◆Oral PresentationPresentation
CEO to present at two upcoming investor conferences in March 2026
◆Oral PresentationPresentation
Participation in Oppenheimer 36th Annual Healthcare Life Sciences Conference
▲FDA Feedback ReceivedTA-ERTFDA Meeting
FDA official meeting minutes received on February 12, 2026, confirming DP PPQ batch requirements
Sanfilippo Syndrome Type B (MPS IIIB)source ↗
◆Poster PresentationPresentation
Long-term data presented at 22nd Annual WORLDSymposium
Sanfilippo Syndrome Type B (MPS IIIB)source ↗
◆Poster Presentationtralesinidase alfaPresentation
Poster presentation on divergent neurocognitive outcomes in MPS IIIB siblings treated with tralesinidase alfa vs supportive management
Sanfilippo syndrome type B (MPS IIIB)source ↗
▲Full Resultstralesinidase alfaClinical Data
Long-term data from interventional studies (201, 202, 401) up to six years
Sanfilippo Syndrome Type B (MPS IIIB)source ↗
◆Oral Presentationtralesinidase alfaPresentation
Platform presentation on long-term administration of tralesinidase alfa enzyme replacement therapy at WORLDSymposium 2026
Sanfilippo syndrome type B (MPS IIIB)source ↗
▲Oral PresentationTA-ERTPresentation
Long-term TA-ERT data presented at WORLDSymposium
MPS IIIBsource ↗
▲Management ChangeCorporate
Appointment of Bruno Gagnon as SVP of Clinical Development Operations
▲Equity OfferingCorporate
Harbour BioMed exercises warrant to acquire common stock in Spruce Biosciences
▲Runway Guidance UpdateCorporate
Cash runway extended into 2027 with initial $15 million tranche
▲Debt Royalty FinancingCorporate
Entered into Loan and Security Agreement with Avenue Capital
●Timing GuidancePresentation
BLA submission for TA-ERT for MPS IIIB expected in Q1 2026
Sanfilippo Syndrome Type B (MPS IIIB)source ↗
▲Type B MeetingTA-ERTFDA Meeting
Type B meeting with FDA in January 2026 to discuss CMC requirements
Sanfilippo Syndrome Type B (MPS IIIB)source ↗
◆Timing GuidancePresentation
BLA submission of TA-ERT for MPS IIIB anticipated in Q1 2026
Sanfilippo Syndrome Type B (MPS IIIB)source ↗
▲Type B MeetingTA-ERTFDA Meeting
Type B meeting with FDA in December 2025 to discuss clinical data and regulatory strategy
Sanfilippo Syndrome Type B (MPS IIIB)source ↗
▲Breakthrough Therapy DesignationDesignation
FDA granted Breakthrough Therapy Designation for TA-ERT for MPS IIIB
Sanfilippo Syndrome Type B (MPS IIIB)source ↗
▲Full ResultsClinical Data
Integrated long-term clinical data of TA-ERT demonstrates profound and durable efficacy and safety in MPS IIIB
Sanfilippo Syndrome Type B (MPS IIIB)source ↗
▲First Patient DosedTildacerfontTrial
First patient dosed in Phase 2 TAMARIND trial of tildacerfont for MDD
Major Depressive Disorder (MDD)source ↗
▼Reverse Stock SplitCorporate
1-for-75 reverse stock split implemented to regain Nasdaq compliance
Past FDA Catalysts and PDUFA Decisions
How SPRB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-09-30 | Tildacerfont | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D26 / 100
Pipeline Score
$4M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 81%
Micro Cap(rank 533 of 658)
Percentile Rank
Spruce Biosciences, Inc. faces pipeline headwinds (26/100), with $60M risk-adjusted pipeline value, led by SPR001 in Congenital Adrenal Hyperplasia (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SPR001 Small moleculeCompletedNCT03687242 | Congenital Adrenal Hyperplasia | Phase 2 | COMPLETED | 35 | Aug 9, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every SPRB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| tralesinidase alfa Breakthrough | Sanfilippo Syndrome Type B (MPS IIIB) | 2026-02-06 | TA-ERT treatment stabilized and preserved cognitive and non-cognitive outcomes for over six-year period; 22 patients followed up to six years; sustained normalization of CSF HS-NRERead More | Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Szwarcberg Javier B.Director, Officer (CHIEF EXECUTIVE OFFICER) | Grant/Award | 266 19,270 held | $4.53 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SPRB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0.6 % (-25 %) | 7.93 M | 121.36 K |
SPRB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SPRB ranks across every disease it competes in
Competitive Position is a premium feature
See how SPRB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSPRB News
SPRB▲ +2.6%today
Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting
Spruce Biosciences has announced the presentation of data from Study 250-902 at the 55th Child Neurology Society Annual Meeting. This study focuses on understanding the progression of MPS IIIB in pediatric patients. The findings aim to shed light on this severe condition and support future therapeutic developments.
Read more →SPRB▼ -5.7%on this news
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Spruce Biosciences, a late-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference. CEO Javier Szwarcberg will present on September 15, 2026, at 2:00 p.m. ET in New York. This event highlights the company's commitment to developing therapies for neurological disorders.
Read more →SPRBSpruce Biosciences Announces Launch of MPS3BStudy.com
Spruce Biosciences has launched MPS3BStudy.com, an online platform aimed at supporting families and caregivers of children with Sanfilippo Syndrome Type B. This resource provides information and facilitates registration of interest in the condition. The initiative reflects the company's commitment to addressing unmet medical needs in neurological disorders.
Read more →SPRB▲ +13.7%on this newsshared move
Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026
Spruce Biosciences has received positive feedback from the FDA regarding its Chemistry, Manufacturing, and Controls (CMC) comparability strategies for the Biologics License Application (BLA). The FDA has confirmed that the planned BLA's content and format are aligned with Spruce's expectations. The company is on track to submit the BLA for TA-ERT in the fourth quarter of 2026.
Read more →SPRBSpruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Spruce Biosciences reported its financial results for Q2 2026, highlighting significant progress in advancing its therapy TA-ERT. The company is on track for a Biologics License Application (BLA) submission in the fourth quarter. This reflects their commitment to addressing unmet medical needs in neurological disorders.
Read more →SPRBCure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
Spruce Biosciences has secured a strategic investment of $5.5 million from the Cure Sanfilippo Foundation and the National MPS Society. This funding will be utilized to support the TA-ERT Expanded Access Program (EAP), enhancing patient access to vital therapies. The investment underscores the commitment to addressing neurological disorders with significant unmet medical needs.
Read more →SPRBSpruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
Spruce Biosciences has appointed Dr. Jessica Cohen Pfeffer as Vice President of Clinical Development. With over ten years of experience in the biopharmaceutical industry, she is expected to strengthen the company's leadership. Spruce focuses on developing therapies for neurological disorders, addressing significant unmet medical needs.
Read more →SPRBSpruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer
Spruce Biosciences has appointed Dr. Adrian Quartel as Chief Medical Officer. With over 25 years of experience in the pharmaceutical industry, Dr. Quartel is expected to lead the company's efforts in developing therapies for neurological disorders. This strategic appointment aligns with Spruce's mission to address significant unmet medical needs.
Read more →SPRBSpruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
Spruce Biosciences, a late-stage biopharmaceutical company, announced its participation in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit. CEO Javier Szwarcberg will engage in a fireside chat, showcasing the company's commitment to addressing neurological disorders. This event underscores the company's ongoing efforts in the healthcare sector.
Read more →SPRBSpruce Biosciences Joins the Russell 3000® Index
Spruce Biosciences has been added to the Russell 3000® Index, which includes the largest U.S. companies. This inclusion may enhance the company's visibility and attract more investors. The Russell 3000® Index is a benchmark for U.S. equity performance, representing a broad spectrum of the market.
Read more →SPRBSpruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs
Spruce Biosciences has appointed Agnieszka Jurecka, M.D., Ph.D., MPH, as the new Vice President of Medical Affairs. This strategic move is aimed at enhancing the company's leadership in medical affairs. Dr. Jurecka brings extensive experience and expertise to the role, which is expected to support Spruce's ongoing initiatives.
Read more →SPRBSpruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller
Spruce Biosciences has appointed Eric Jordan as Vice President of Marketing and Tina Gullotta as Vice President of Finance and Corporate Controller. This leadership change aims to strengthen the company's marketing and financial strategies. The appointments reflect the company's commitment to enhancing its operational capabilities.
Read more →SPRBSpruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium
Spruce Biosciences announced the presentation of long-term data on Tralesinidase Alfa, an enzyme replacement therapy for Sanfilippo Syndrome Type B (MPS IIIB), at the 18th International MPS Symposium. The announcement highlights the company's ongoing commitment to addressing this rare genetic disorder. Details regarding the specific findings or implications of the data were not provided in the article.
Read more →SPRBSpruce Biosciences Announces Data Presentation at the 18th International MPS Symposium
Spruce Biosciences has announced a data presentation at the 18th International MPS Symposium. The event is significant for showcasing advancements in the field. However, specific details about the data or findings were not disclosed in the announcement. The presentation is expected to attract attention from industry professionals.
Read more →SPRBSpruce Biosciences to Participate in Upcoming Conferences in June
Spruce Biosciences is scheduled to participate in several conferences in June. The details regarding the specific conferences and topics of discussion have not been disclosed. This participation may provide opportunities for networking and showcasing their developments in the biopharma sector.
Read more →SPRBSpruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Spruce Biosciences has released its financial results for the first quarter of 2026 along with corporate updates. The report provides insights into the company's performance and strategic direction. Further details on specific financial metrics or corporate developments were not disclosed in the article.
Read more →SPRBSpruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations
Spruce Biosciences has announced the appointment of Brian Walls as Vice President of Market Access and Darren Johnson as Vice President of Commercial Operations. These appointments are aimed at strengthening the company's commercial leadership team. The announcement reflects the company's commitment to enhancing its market presence and operational efficiency.
Read more →SPRB▼ -26%on this news
Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Spruce Biosciences has priced its public offering at $50 per share, aiming to raise $60 million. The offering includes 1,150,000 shares of common stock and 50,000 pre-funded warrants. The expected closing date is April 22, 2026, pending customary conditions. The company is focused on developing therapies for neurological disorders.
Read more →About Spruce Biosciences, Inc.
Headquarters611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next SPRB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime